NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
523
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
stocks
Ask the analyst: What to expect in earnings season?
stocks
ASX healthcare share remains undervalued ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.80 | 36.20 | 0.40% |
| CAC 40 | 8,435.81 | 63.53 | 0.76% |
| DAX 40 | 25,447.82 | 348.82 | 1.39% |
| Dow JONES (US) | 52,239.94 | 292.69 | 0.56% |
| FTSE 100 | 10,817.21 | 80.98 | 0.75% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,947.45 | 28.38 | -0.11% |
| Nikkei 225 | 64,931.19 | 320.04 | 0.50% |
| NZX 50 Index | 13,850.69 | 78.40 | 0.57% |
| S&P 500 | 7,417.93 | 5.95 | 0.08% |
| S&P/ASX 200 | 8,894.00 | 36.10 | 0.41% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |